KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Thermo Fisher Scientific (TMO) EBITDA (2016 - 2025)

Thermo Fisher Scientific's EBITDA history spans 17 years, with the latest figure at $2.3 billion for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 11.86% year-over-year to $2.3 billion, compared with a TTM value of $7.7 billion through Dec 2025, up 5.57%, and an annual FY2025 reading of $7.7 billion, up 5.57% over the prior year.
  • EBITDA for Q4 2025 was $2.3 billion at Thermo Fisher Scientific, up from $1.9 billion in the prior quarter.
  • The five-year high for EBITDA was $3.0 billion in Q2 2021, with the low at $1.6 billion in Q2 2023.
  • Average EBITDA over 5 years is $2.0 billion, with a median of $1.9 billion recorded in 2022.
  • Year-over-year, EBITDA skyrocketed 236.53% in 2021 and then crashed 44.59% in 2023.
  • Tracing TMO's EBITDA over 5 years: stood at $2.5 billion in 2021, then fell by 26.67% to $1.9 billion in 2022, then decreased by 0.38% to $1.9 billion in 2023, then rose by 8.74% to $2.0 billion in 2024, then rose by 11.86% to $2.3 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's EBITDA are $2.3 billion (Q4 2025), $1.9 billion (Q3 2025), and $1.8 billion (Q2 2025).